Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.

< BACK TO ARCHIVE


Papers: 12 Jun 2021 - 18 Jun 2021


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2021 Jun 11


Headache


http://www.ncbi.nlm.nih.gov/pubmed/34115380?dopt=Abstract

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.

Authors

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
Ashina M, Cohen JM, Gandhi SK, Du E
Headache. 2021 Jun 11.
PMID: 34115380.

Abstract

To evaluate the impact of fremanezumab on the severity and duration of remaining migraine attacks in patients with chronic migraine (CM) or episodic migraine (EM).
Read This Paper